OptiBiotix Health (OPTI.L) Osake Kurssi
OptiBiotix Health Kurssi
Liikevaihto on kasvanut 22,0 % vuodessa viimeisten 14 vuoden aikana 1,17 M GBP:een. Osakekohtainen tulos on kasvanut 4,9 % vuodessa viimeisten 5 vuoden aikana. OptiBiotix Healthn nettomarginaali on nyt −333,6 %, laskenut 282,9 %:sta muutama vuosi sitten.
OptiBiotix Health osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
OptiBiotix Health liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset OptiBiotix Health -osakkeesta
OptiBiotix Health PLC is a company focused on developing and commercializing microbial strains and compounds, which have the potential to impact human health. Their business model revolves around identifying and understanding specific health conditions and using science-based solutions to develop innovative and effective products. OptiBiotix Health PLC aims to address various health concerns, including obesity, diabetes, and cholesterol management, by utilizing their expertise in the microbiome and actively collaborating with commercial partners. By leveraging cutting-edge research and technologies, they strive to provide evidence-based and clinically-supported solutions to improve human health and well-being.
OptiBiotix Health PLC is primarily active in the healthcare and biotechnology industries.
The main competitors of OptiBiotix Health PLC in the market are other companies operating in the field of probiotics and microbiome-based health and wellness products. These competitors include established players like Probi AB, DuPont Nutrition & Biosciences, and Chr. Hansen Holding A/S. With its innovative products and scientific approach, OptiBiotix Health PLC competes for market share in the rapidly growing global probiotics industry. By leveraging its proprietary technologies and research, OptiBiotix Health PLC aims to differentiate itself and carve a niche in the market.
OptiBiotix Health PLC is a UK-based company focused on developing and commercializing innovative products that target human microbiome modulation. Founded in 2014, OptiBiotix has quickly gained recognition in the field of science-driven microbiome research. The company collaborates with leading academic institutions and industry partners to develop microbiome-based therapeutics, probiotics, and functional ingredients. OptiBiotix's proprietary technology platform provides a solid foundation for advancing their product pipeline, which includes well-researched applications in weight management, cholesterol reduction, and cardiovascular health. These groundbreaking efforts, combined with relentless dedication to leading-edge research and development, have earned OptiBiotix a distinguished reputation in the microbiome and biotechnology sectors.
OptiBiotix Health PLC, a leading company in the healthcare industry, has achieved several significant milestones. Firstly, the company successfully developed and launched OptiBiotix's flagship product, SlimBiome®. This innovative weight management ingredient has gained immense popularity due to its effectiveness in promoting healthy weight loss. Moreover, OptiBiotix Health PLC has formed strategic partnerships with renowned companies and organizations. Collaborations with major players such as DSM, Tata Chemicals, and Seed Health have further expanded the company's reach and market presence. Additionally, OptiBiotix Health PLC has received numerous accolades and awards, recognizing its exceptional contributions to the health and wellness sector. These accomplishments reflect the company's commitment to providing quality products and driving advancements in the field of microbiome science. Overall, OptiBiotix Health PLC's achievements demonstrate its dedication to delivering innovative solutions for better health and its continuous efforts towards improving the well-being of individuals worldwide.
OptiBiotix Health PLC is primarily present in the United Kingdom, Europe, and the United States.
OptiBiotix Health PLC represents values focused on promoting health and wellbeing through innovative solutions. The company's corporate philosophy centers around scientific excellence, research-driven development, and collaboration with industry leaders. OptiBiotix Health PLC aims to improve people's lives by offering scientifically validated products that target and support gut microbiome modulation. With a strong emphasis on cutting-edge probiotic research and advanced microbiome science, OptiBiotix Health PLC is committed to delivering effective and evidence-based solutions to meet the growing demand for gut health enhancement.
7 analyytikkoa arvioi tällä hetkellä OptiBiotix Health-osaketta: 0 suosittaa ostoa, 3 pitoa ja 4 myyntiä.
Nykyisellä valuuttakurssilla OptiBiotix Health-osake noteerataan hintaan 0,07 EUR (0,06 GBP).
OptiBiotix Health-osake (OPTI.L) on listattuna 3 pörssissä, muun muassa: London (OPTI.L), Frankfurt (OB3.F).
OptiBiotix Health PLC is a biotechnology company based in the United Kingdom, specializing in the development and commercialization of dietary supplements and functional/probiotic premium compounds. The core business of OptiBiotix Health is the creation of proprietary products designed to improve the health and well-being of its customers. The company focuses on the development of prebiotics that support the body's natural gut bacteria to resolve digestive issues, strengthen the immune system, and reduce the risk of diseases, among other benefits. OptiBiotix Health's product range also includes probiotics that contain a high concentration of healthy bacteria. These products help protect and support digestion and promote positive gut health. The products are available in the form of supplements and can be found in the beverage and food industry, as well as in applications for animal husbandry. OptiBiotix Health has a comprehensive research and development department that continually works to explore new markets and applications. The company offers a product range of over 20 different products and collaborates with numerous customers in the food industry. The company also aims to develop innovative solutions for global health issues, such as new therapies to combat obesity, diabetes, and cholesterol levels, as well as optimize gut health. OptiBiotix Health operates based on B2B distribution partnerships and has agreements with many leading companies in the food and beverage industry. The partners use OptiBiotix Health's proprietary products in their own products and integrate them into their manufacturing process. The partners benefit from the patented premium compounds and can enhance their products accordingly. In addition to the B2B distribution partnerships, OptiBiotix Health has legal agreements with production companies to enable them to produce the products based on the unique and patented formulations. OptiBiotix Health examines all stages of the value chain to ensure that the high quality of the products is maintained even in the subordinate production steps. Overall, OptiBiotix Health PLC has developed an innovative business model by focusing on intensive research and the development of proprietary products. Together with a network of business partners and distribution channels, OptiBiotix Health is able to serve its market globally and enter into licensing agreements with many retailers.
Liikevaihtoa ei voida laskea OptiBiotix Health:lle tällä hetkellä.
Voittoa ei voida laskea OptiBiotix Health:lle tällä hetkellä.
P/E-suhdetta ei voida laskea OptiBiotix Health:lle tällä hetkellä.
P/S-suhdetta ei voida laskea OptiBiotix Health:lle tällä hetkellä.
OptiBiotix Health:n Eulpool-laatuscore on 5/10.
OptiBiotix Health:n ISIN on GB00BP0RTP38. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
OptiBiotix Health:n WKN on A118S6. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
OptiBiotix Health:n ticker on OPTI.L. Tämä pörssinoteeraus käytetään OptiBiotix Health-osakkeiden kauppaan pörssissä.
OptiBiotix Health osake
OptiBiotix Health vertaisryhmä
OptiBiotix Health Ticker
OptiBiotix Health FIGI
Kaikki tunnusluvut ja syvällinen analyysi OptiBiotix Health:sta
Meidän osakeanalyysimme OptiBiotix Health-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut OptiBiotix Health:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: